ClinicalTrials.gg
Active, not recruitingNCT05731128Updated Jun 23, 2026

A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))

A Phase 2 interventional study of Dupilumab and Placebo in Colitis Ulcerative, sponsored by Sanofi. Active, not recruiting at 77 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Colitis, Ulcerative by Sanofi — 3 open to participants now, 6 under way, 2 of them phase 3. Colitis, Ulcerative · Sanofi.

Enrollment
7th of 12
68 · median 87
Started
2023
the only one that year
Phase 2
8 of 12
none open now
Registered
6th of 12
by date

Among the 12 studies in Colitis, Ulcerative by Sanofi, this one is the 7th largest by enrollment, is the only one that started in 2023, is one of 8 in phase 2, and was the 6th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

3 of the 12 studies in Colitis, Ulcerative by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Colitis, Ulcerative by Sanofi, or all of them as a file.
02

Study summary

The protocol of this Phase 2 clinical trial consists of a double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of dupilumab in participants with moderately to severely active Ulcerative Colitis (UC) with an eosinophilic phenotype.

Screening period: 2 to up to 4 weeks

Treatment period:

52-week investigational medicinal product (IMP) intervention (dupilumab or matching placebo) from Week 0 to Week 52 Open-label arm (optional): administration of open-label dupilumab therapy for study participants who qualify. Follow-up period: 12 weeks The maximum duration of study per participant is up to 68 weeks.

03

Conditions studied

  • Colitis Ulcerative

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be ≥18 years of age at the time of signing the .
  • Evidence of biomarker enrichment at time of screening.
  • Moderately to severely active UC, defined as a baseline modified Mayo score of 5 to 9, inclusive, using the Mayo endoscopic subscore assigned during the concurrent local and central reading of the video endoscopy.
  • Has a screening endoscopy with ≥2 endoscopic subscore in the Mayo score component assessment as determined by concurrent local and central reading of the video endoscopy.
  • Has a baseline rectal bleeding subscore of ≥1 and baseline a stool frequency score of ≥1 as determined by the Mayo score component assessment.
  • Participants with inadequate response/non-response, loss of response, or are intolerant of standard biologic therapy for their UC AND/OR Inadequate or non-responders, have shown loss of response, or are intolerant to at least 1 of the following treatments: oral (≤20 mg/day), 5-aminosalicylic acid (ASA) compounds, immunomodulators, small molecules.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Severe extensive colitis as evidenced by:

    • Current hospitalization
    • Likely to require surgery for the treatment of UC within 12 weeks of Screening Visit
  • UC limited to the rectum only or to \<20 cm of the colon as determined by central reading.
  • Presence of an ileal pouch, ostomy, stoma or fistula or history of a fistula.
  • Require, or required within the 2 months before screening, surgery for active gastrointestinal bleeding, peritonitis, intestinal obstruction, or intra-abdominal or pancreatic abscess requiring surgical drainage, or other conditions possibly confounding the evaluation of benefit from study agent treatment.
  • Has a prior medical history of eosinophilic colitis.
  • Participants with abdominal abscess, fulminant disease, or toxic megacolon.
  • Participants with intestinal failure or short bowel syndrome.
  • Presence of symptomatic colonic or small bowel obstruction, confirmed by objective radiographic or endoscopic evidence of a stricture with resulting obstruction (dilation of the colon or small bowel proximal to the stricture on barium radiograph or an inability to traverse the stricture at endoscopy).
  • History of extensive colonic resection (eg, less than 30 cm of colon remaining) that would prevent adequate evaluation of the effect of study agent on clinical disease activity.
  • History of colonic mucosal dysplasia or presence of adenomatous colonic polyps not removed OR presence of colonic mucosal dysplasia or adenomatous colonic polyps not removed during colonoscopy at screening visit.
  • If the participant has extensive colitis for ≥8 years or disease limited to left side of colon (ie, distal to splenic flexure) for >10 years, regardless of age, a colonoscopy within 1 year of the screening visit is required to survey for dysplasia. Participants with dysplasia or cancer identified on will be excluded.
  • Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, or Crohn's disease or clinical findings suggestive of Crohn's disease.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Dupilumab

    Initial loading dose followed by regular administration for the duration of the treatment period.

    Drug: Dupilumab

  • Placebo comparator
    Placebo

    Initial loading dose followed by regular administration for the duration of the treatment period.

    Drug: Placebo

  • Other
    Open-label arm (optional)

    Regular administration of open label dupilumab

    Drug: Dupilumab

Interventions

  • injection solution subcutaneous

    Also known as: Dupixent

  • DrugPlacebo

    injection solution subcutaneous

06

What researchers measure

Primary outcomes

  1. Proportion of participants achieving clinical response at Week 24

    Clinical response by modified Mayo score is defined as a decrease from baseline in the modified Mayo score of ≥2 points and at least a 30% reduction from baseline, and a decrease in rectal bleeding subscore of ≥1 OR an absolute rectal bleeding subscore of 0 or 1. The modified Mayo score consists of 3 subscores; a patient-reported subscore for rectal bleeding, a patient-reported subscore for stool frequency, and a Mayo endoscopic subscore. Each subscore ranges 0-3 with higher scores indicating greater disease severity. The total modified Mayo score ranges 0-9 with higher scores indicating greater disease severity.

    Time frame: Week 24

Secondary outcomes

  1. Proportion of participants who are in clinical response at Week 52

    Clinical response by modified Mayo score is defined as a decrease from baseline in the modified Mayo score of ≥2 points and at least a 30% reduction from baseline, and a decrease in rectal bleeding subscore of ≥1 OR an absolute rectal bleeding subscore of 0 or 1. The modified Mayo score consists of 3 subscores; a patient-reported subscore for rectal bleeding, a patient-reported subscore for stool frequency, and a Mayo endoscopic subscore. Each subscore ranges 0-3 with higher scores indicating greater disease severity. The total modified Mayo score ranges 0-9 with higher scores indicating greater disease severity.

    Time frame: Week 52

  2. Proportion of participants who are in clinical remission at Week 24 and Week 52

    Clinical remission by modified Mayo score is defined as a modified Mayo score of ≤2 with a stool frequency score ≤1, a rectal bleeding score = 0, AND a Mayo endoscopic subscore ≤1 with absence of friability. The modified Mayo score consists of 3 subscores; a patient-reported subscore for rectal bleeding, a patient-reported subscore for stool frequency, and a Mayo endoscopic subscore. Each subscore ranges 0-3 with higher scores indicating greater disease severity. The total modified Mayo score ranges 0-9 with higher scores indicating greater disease severity.

    Time frame: Week 24 and Week 52

  3. Proportion of participants in symptomatic remission over time

    Symptomatic remission is defined as Mayo stool frequency score = 0, or Mayo stool frequency score = 1 with a ≥1-point decrease from baseline, and Mayo rectal bleeding score = 0.

    Time frame: Baseline up to Week 52

  4. Proportion of participants achieving histologic-endoscopic healing at Week 24, and Week 52

    Histologic-endoscopic healing is defined by Mayo endoscopic subscore of 0 or 1 and histological healing (Geboes score \<2). Mayo endoscopic subscore ranges 0-3 with higher scores indicating greater disease severity. The Geboes Index score is a six-grade classification system for inflammation: Grade 0 - structural change only; Grade 1 -chronic inflammation; Grade 2 - lamina propria neutrophils; Grade 3 - neutrophils in epithelium; Grade 4 - crypt destruction; and Grade 5 - erosions or ulcers.

    Time frame: Week 24 and Week 52

  5. Proportion of participants with a Mayo endoscopic subscore of 0 or 1 without friability at Week 24, and Week 52

    The Mayo endoscopic subscore ranges 0-3 with higher scores indicating greater disease severity.

    Time frame: Week 24 and Week 52

  6. Proportion of participants with a Mayo endoscopic subscore of 0 at Week 24, and Week 52

    The Mayo endoscopic subscore ranges 0-3 with higher scores indicating greater disease severity.

    Time frame: Week 24 and Week 52

  7. Change from baseline in the partial Mayo score at Week 8, Week 24, and Week 52

    The partial Mayo score consists of 3 subscores; a patient-reported subscore for rectal bleeding, a patient-reported subscore for stool frequency, and a Physician's global assessment (PGA) subscore. Each subscore ranges 0-3 with higher scores indicating greater disease severity. The partial Mayo score ranges 0-9 with higher scores indicating greater disease severity.

    Time frame: Baseline to Week 8, Week 24 and Week 52

  8. Proportion of participants in clinical remission at Week 52 who are off concomitant oral corticosteroids (OCS) at least 4 weeks prior to Week 52

    Clinical remission by modified Mayo score is defined as a modified Mayo score of ≤2 with a stool frequency score ≤1, a rectal bleeding score = 0, AND a Mayo endoscopic subscore ≤1 with absence of friability. The modified Mayo score consists of 3 subscores; a patient-reported subscore for rectal bleeding, a patient-reported subscore for stool frequency, and a Mayo endoscopic subscore. Each subscore ranges 0-3 with higher scores indicating greater disease severity. The total modified Mayo score ranges 0-9 with higher scores indicating greater disease severity.

    Time frame: Baseline up to Week 52

  9. Proportion of participants in clinical remission at Week 52 who are off concomitant oral corticosteroids (OCS) at least 4 weeks prior to Week 52 among participants receiving OCS at baseline

    Clinical remission by modified Mayo score is defined as a modified Mayo score of ≤2 with a stool frequency score ≤1, a rectal bleeding score = 0, AND a Mayo endoscopic subscore ≤1 with absence of friability. The modified Mayo score consists of 3 subscores; a patient-reported subscore for rectal bleeding, a patient-reported subscore for stool frequency, and a Mayo endoscopic subscore. Each subscore ranges 0-3 with higher scores indicating greater disease severity. The total modified Mayo score ranges 0-9 with higher scores indicating greater disease severity.

    Time frame: Baseline up to Week 52

  10. Change from baseline in abdominal pain assessed by Abdominal Pain Numerical Rating Scale (NRS) at Week 8, Week 24, and Week 52

    Abdominal pain NRS is a single item patient report outcome (PRO) tool that patients will use to report intensity of their worst abdominal pain during a daily recall period with 0 being 'no pain' and 10 being the 'worst pain imaginable'.

    Time frame: Baseline to Week 8, Week 24 and Week 52

  11. Incidence of treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs)

    Time frame: Baseline up to Week 64

  12. Concentration of dupilumab in serum over time.

    Time frame: Baseline up to Week 64

  13. Incidence of treatment-emergent antidrug antibodies (ADA) against dupilumab.

    Time frame: Baseline up to Week 64

  14. Change from baseline (Screening visit) in the normalized enrichment scores (NES) in type 2 inflammation transcriptome signature at Week 24 and Week 52.

    NES is a summary score of the expression of a specified set of genes defining a molecular phenotype.

    Time frame: Baseline to Week 24 and Week 52

07

Study locations

77 sites
  • Om Research- Site Number : 8400029
    Apple Valley, California 92307, United States
  • TLC Clinical Research- Site Number : 8400020
    Beverly Hills, California 90211, United States
  • Om Research - Oxnard- Site Number : 8400028
    Oxnard, California 93036, United States
  • Palmtree Clinical Research- Site Number : 8400048
    Palm Springs, California 92262, United States
  • Clinical Trials Management Services - Thousand Oaks- Site Number : 8400034
    Thousand Oaks, California 91360, United States
  • Homestead Associates in Research- Site Number : 8400004
    Homestead, Florida 33033, United States
  • Wellness Clinical Research - Miami Lakes - 8181 Northwest 154th Street- Site Number : 8400009
    Miami Lakes, Florida 33016, United States
  • GI Pros- Site Number : 8400046
    Naples, Florida 34102, United States
  • Advanced Research Institute - New Port Richey- Site Number : 8400026
    New Port Richey, Florida 34653, United States
  • Digestive Disease Consultants - Orange Park- Site Number : 8400042
    Orange Park, Florida 32073, United States
  • Tellabio International Research Services- Site Number : 8400041
    Pembroke Pines, Florida 33025, United States
  • GCP Clinical Research- Site Number : 8400014
    Tampa, Florida 33609, United States
  • Gastroenterology Consultants - Roswell- Site Number : 8400022
    Roswell, Georgia 30076, United States
  • Sanmora Bespoke Clinical Research Solutions- Site Number : 8400043
    East Orange, New Jersey 07018, United States
  • Smart Medical Research - New York- Site Number : 8400037
    Jackson Heights, New York 11372, United States
  • DiGiovanna Family Care- Site Number : 8400006
    Massapequa, New York 11758, United States
  • Tryon Medical Partners - Charlotte - Piedmont Row Drive South- Site Number : 8400008
    Charlotte, North Carolina 28287, United States
  • Care Access - Lumberton- Site Number : 8400018
    Lumberton, North Carolina 28358, United States
  • UPMC Presbyterian- Site Number : 8400038
    Pittsburgh, Pennsylvania 15213, United States
  • Advanced Gastroenterology Associates - Decatur- Site Number : 8400047
    Decatur, Texas 76234, United States
  • Katy Integrative Gastroenterology- Site Number : 8400027
    Katy, Texas 77494, United States
  • Medrasa Clinical Research - Medrasa Sherman- Site Number : 8400039
    Sherman, Texas 75092, United States
  • Texas Digestive Disease Consultants - Southlake- Site Number : 8400013
    Southlake, Texas 76092, United States
  • Digestive Health Specialists of Tyler- Site Number : 8400031
    Tyler, Texas 75701, United States
  • Victoria Gastroenterology- Site Number : 8400019
    Victoria, Texas 77904, United States
  • Washington Gastroenterology - Bellevue- Site Number : 8400025
    Bellevue, Washington 98004, United States
  • Washington Gastroenterology - Tacoma- Site Number : 8400030
    Tacoma, Washington 98405, United States
  • Investigational Site Number : 0320006
    Mar del Plata, Buenos Aires 7600, Argentina
  • Investigational Site Number : 0320001
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Investigational Site Number : 0320004
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Investigational Site Number : 0320007
    Buenos Aires, 1028, Argentina
  • Investigational Site Number : 0320008
    Buenos Aires, 1119, Argentina
  • Investigational Site Number : 0320002
    Buenos Aires, 1125, Argentina
  • Investigational Site Number : 1240007
    Edmonton, Alberta T5R 1W2, Canada
  • Investigational Site Number : 1240010
    Scarborough Village, Ontario M1B 3V4, Canada
  • Investigational Site Number : 1240006
    Montreal, Quebec H1T 2M4, Canada
  • Investigational Site Number : 1240003
    Montreal, Quebec H3G 1A4, Canada
  • Investigational Site Number : 1520001
    Concepción, Biobio 4070038, Chile
  • Investigational Site Number : 1520005
    Santiago, Reg Metropolitana de Santiago 7620001, Chile
  • Investigational Site Number : 1520003
    Santiago, Reg Metropolitana de Santiago 8330034, Chile
  • Investigational Site Number : 1520006
    Santiago, Reg Metropolitana de Santiago 8360156, Chile
  • Investigational Site Number : 1520002
    Santiago, Reg Metropolitana de Santiago 8380456, Chile
  • Investigational Site Number : 3920006
    Nagoya, Aichi-ken 451-8511, Japan
  • Investigational Site Number : 3920005
    Kashiwa, Chiba 277-0871, Japan
  • Investigational Site Number : 3920008
    Kitakyushu, Fukuoka 802-0077, Japan
  • Investigational Site Number : 3920002
    Sapporo, Hokkaido 004-0041, Japan
  • Investigational Site Number : 3920001
    Sapporo, Hokkaido 065-0033, Japan
  • Investigational Site Number : 3920011
    Kamakura, Kanagawa 247-0056, Japan
  • Investigational Site Number : 3920010
    Shimizu, Shizuoka 411-0905, Japan
  • Investigational Site Number : 3920004
    Bunkyo, Tokyo 113-8510, Japan
  • Investigational Site Number : 3920007
    Kyoto, 605-0981, Japan
  • Investigational Site Number : 3920009
    Saitama, 336-0963, Japan
  • Investigational Site Number : 4840005
    Saltillo, Coahuila 25020, Mexico
  • Investigational Site Number : 4840002
    Torreón, Coahuila 27000, Mexico
  • Investigational Site Number : 4840007
    Guadalajara, Jalisco 44100, Mexico
  • Investigational Site Number : 4840004
    Mexico City, Mexico City 01120, Mexico
  • Investigational Site Number : 4840003
    Chihuahua City, 31000, Mexico
  • University of Puerto Rico - Medical Sciences Campus- Site Number : 6300002
    San Juan, 00936, Puerto Rico
  • Investigational Site Number : 7100005
    Cape Town, 7405, South Africa
  • Investigational Site Number : 7100009
    Cape Town, 7500, South Africa
  • Investigational Site Number : 7100002
    Cape Town, 7708, South Africa
  • Investigational Site Number : 7100007
    Cape Town, 7800, South Africa
  • Investigational Site Number : 7100006
    Johannesburg, 1821, South Africa
  • Investigational Site Number : 7100001
    Johannesburg, 2193, South Africa
  • Investigational Site Number : 7100008
    Kempton Park, 1619, South Africa
  • Investigational Site Number : 7100003
    Port Elizabeth, 6045, South Africa
  • Investigational Site Number : 7100004
    Pretoria, 0002, South Africa
  • Investigational Site Number : 4100003
    Haeundae-gu, Busan 48108, South Korea
  • Investigational Site Number : 4100005
    Daegu, Daegu 41944, South Korea
  • Investigational Site Number : 4100006
    Daejeon, Daejeon 34943, South Korea
  • Investigational Site Number : 4100002
    Wŏnju, Gangwon-do 26426, South Korea
  • Investigational Site Number : 4100004
    Daegu, Gyeongsangbuk-do 42415, South Korea
  • Investigational Site Number : 1580002
    Taichung, 404, Taiwan
  • Investigational Site Number : 7920003
    Gaziantep, 27310, Turkey (Türkiye)
  • Investigational Site Number : 7920005
    Istanbul, 34734, Turkey (Türkiye)
  • Investigational Site Number : 7920001
    Mersin, 33070, Turkey (Türkiye)
  • Investigational Site Number : 7920006
    Zonguldak, 67000, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized, and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in May 2026, 40 months.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 40 months is above that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2023
First posted
Feb 16, 2023
StartActual
Jan 12, 2023
Primary completionActual
May 13, 2026
CompletionEst.
Feb 22, 2027
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05731128
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Feb 16, 2023
Start date
Jan 12, 2023
Primary completion
May 13, 2026
Completion
Feb 22, 2027 (estimated)
Last update
Jun 23, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion